Mesoblast Limited (MESO)
USD 9.85
(-6.81%)
USD 9.85
(-6.81%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 5.9 Million USD | -16.82% |
| 2023 | 76.79 Million USD | -15.42% |
| 2022 | 90.78 Million USD | -21.1% |
| 2021 | 115.05 Million USD | 6.97% |
| 2020 | 107.56 Million USD | 9.89% |
| 2019 | 97.88 Million USD | 6.36% |
| 2018 | 92.03 Million USD | -0.5% |
| 2017 | 92.49 Million USD | -6.03% |
| 2016 | 98.43 Million USD | -28.22% |
| 2015 | 137.13 Million USD | 39.43% |
| 2014 | 98.35 Million USD | 10.68% |
| 2013 | 88.86 Million USD | 36.74% |
| 2012 | 64.98 Million USD | 139.28% |
| 2011 | 27.15 Million USD | 143.97% |
| 2010 | 11.13 Million USD | 7.87% |
| 2009 | 10.31 Million USD | 16.61% |
| 2008 | 8.84 Million USD | 1.8% |
| 2007 | 8.69 Million USD | -4.54% |
| 2006 | 9.1 Million USD | 511.37% |
| 2005 | 1.48 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.21 Million USD | -84.58% |
| 2024 FY | 48.97 Million USD | -36.22% |
| 2024 Q2 | 3.21 Million USD | 0.0% |
| 2023 Q3 | 16.4 Million USD | -25.32% |
| 2023 Q4 | 20.87 Million USD | 27.29% |
| 2023 FY | 76.79 Million USD | -15.42% |
| 2023 Q1 | 17.5 Million USD | -20.53% |
| 2023 Q2 | 21.96 Million USD | 25.45% |
| 2022 Q3 | 21.35 Million USD | -13.21% |
| 2022 Q2 | 24.6 Million USD | 7.33% |
| 2022 Q1 | 22.92 Million USD | 7.66% |
| 2022 FY | 90.78 Million USD | -21.1% |
| 2022 Q4 | 22.03 Million USD | 3.18% |
| 2021 FY | 115.05 Million USD | 6.97% |
| 2021 Q1 | 38.86 Million USD | 18.89% |
| 2021 Q2 | 28.55 Million USD | -26.53% |
| 2021 Q4 | 21.29 Million USD | -23.48% |
| 2021 Q3 | 27.82 Million USD | -2.57% |
| 2020 Q4 | 32.69 Million USD | 17.93% |
| 2020 Q2 | 25.92 Million USD | 26.14% |
| 2020 Q3 | 27.72 Million USD | 6.94% |
| 2020 Q1 | 20.55 Million USD | 5.19% |
| 2020 FY | 107.56 Million USD | 9.89% |
| 2019 Q3 | 22.93 Million USD | -12.03% |
| 2019 Q1 | 28.42 Million USD | 14.55% |
| 2019 Q2 | 26.06 Million USD | -8.28% |
| 2019 FY | 97.88 Million USD | 6.36% |
| 2019 Q4 | 19.53 Million USD | -14.8% |
| 2018 Q2 | 22.34 Million USD | 8.15% |
| 2018 Q1 | 20.66 Million USD | -13.6% |
| 2018 Q4 | 24.81 Million USD | 0.54% |
| 2018 FY | 92.03 Million USD | -0.5% |
| 2018 Q3 | 24.67 Million USD | 10.42% |
| 2017 Q3 | 22.88 Million USD | -2.18% |
| 2017 FY | 92.49 Million USD | -6.03% |
| 2017 Q4 | 23.91 Million USD | 4.51% |
| 2017 Q2 | 23.39 Million USD | 5.03% |
| 2017 Q1 | 22.27 Million USD | -18.56% |
| 2016 Q1 | 21.72 Million USD | -63.19% |
| 2016 Q4 | 27.35 Million USD | 11.56% |
| 2016 FY | 98.43 Million USD | -28.22% |
| 2016 Q2 | 24.84 Million USD | 14.38% |
| 2016 Q3 | 24.51 Million USD | -1.32% |
| 2015 Q4 | 59 Million USD | 141.18% |
| 2015 Q1 | 16.61 Million USD | -13.46% |
| 2015 Q3 | 24.46 Million USD | -18.75% |
| 2015 FY | 137.13 Million USD | 39.43% |
| 2015 Q2 | 30.11 Million USD | 81.25% |
| 2014 FY | 98.35 Million USD | 10.68% |
| 2014 Q3 | 19.49 Million USD | 21.32% |
| 2014 Q2 | 16.06 Million USD | -10.69% |
| 2014 Q1 | 17.98 Million USD | 2.95% |
| 2014 Q4 | 19.19 Million USD | -1.52% |
| 2013 Q1 | 17.31 Million USD | 0.0% |
| 2013 Q3 | 19.86 Million USD | 14.65% |
| 2013 Q4 | 17.47 Million USD | -12.05% |
| 2013 FY | 88.86 Million USD | 36.74% |
| 2013 Q2 | 17.32 Million USD | 0.06% |
| 2012 FY | 64.98 Million USD | 139.28% |
| 2011 FY | 27.15 Million USD | 143.97% |
| 2010 FY | 11.13 Million USD | 7.87% |
| 2009 FY | 10.31 Million USD | 16.61% |
| 2008 FY | 8.84 Million USD | 1.8% |
| 2007 FY | 8.69 Million USD | -4.54% |
| 2006 FY | 9.1 Million USD | 511.37% |
| 2005 FY | 1.48 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 97.856% |
| Alkermes plc | 996.24 Million USD | 99.408% |
| Agenus Inc. | 78.18 Million USD | 92.451% |
| Aptorum Group Limited | 10.56 Thousand USD | -55758.414% |
| Ardelyx, Inc. | 169.93 Million USD | 96.527% |
| Dyadic International, Inc. | 9.15 Million USD | 35.516% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | 73.478% |
| Lantern Pharma Inc. | 17.87 Million USD | 66.987% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | 12.328% |
| Novavax, Inc. | 779.12 Million USD | 99.242% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 92.719% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 92.82% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | 69.606% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | 80.065% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 88.891% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 98.449% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 75.719% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 84.415% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | 80.82% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 93.033% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 66.191% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 96.496% |
| Clearside Biomedical, Inc. | 32.71 Million USD | 81.959% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 96.306% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 99.672% |
| AlloVir, Inc. | 180.93 Million USD | 96.738% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 98.676% |
| VYNE Therapeutics Inc. | 29.68 Million USD | 80.116% |
| Bicycle Therapeutics plc | 216.92 Million USD | 97.279% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 96.567% |
| ChromaDex Corporation | 56.37 Million USD | 89.532% |
| Chimerix, Inc. | 93.38 Million USD | 93.68% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | 57.569% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 96.079% |
| CRISPR Therapeutics AG | 463.49 Million USD | 98.727% |
| Precision BioSciences, Inc. | 92.46 Million USD | 93.617% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 97.677% |
| Fortress Biotech, Inc. | 200.19 Million USD | 97.052% |
| Fortress Biotech, Inc. | 200.19 Million USD | 97.052% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | 81.976% |
| ImmuCell Corporation | 9.61 Million USD | 38.632% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 96.26% |
| Immix Biopharma, Inc. | 16.14 Million USD | 63.435% |
| Incyte Corporation | 1.19 Billion USD | 99.504% |
| Innoviva, Inc. | 132.15 Million USD | 95.534% |
| IO Biotech, Inc. | 91.44 Million USD | 93.546% |
| Jaguar Health, Inc. | 42.01 Million USD | 85.953% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 96.513% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 93.001% |
| ContextLogic Inc. | 387 Million USD | 98.475% |
| MiMedx Group, Inc. | 229.72 Million USD | 97.431% |
| MEI Pharma, Inc. | 34.78 Million USD | 83.033% |
| NextCure, Inc. | 67.63 Million USD | 91.274% |
| Onconetix, Inc. | 34.9 Million USD | 83.092% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | 53.695% |
| Opthea Limited | 191.96 Million USD | 96.926% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -114.495% |
| Vaxcyte, Inc. | 468.04 Million USD | 98.739% |
| PDS Biotechnology Corporation | 43.04 Million USD | 86.289% |
| Precigen, Inc. | 84.18 Million USD | 92.989% |
| Pharming Group N.V. | 225.49 Million USD | 97.383% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 96.483% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 91.867% |
| PureTech Health plc | 144.59 Million USD | 95.918% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 95.469% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 97.593% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 75.719% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 97.419% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | 80.874% |
| Acelyrin, Inc. | 422.06 Million USD | 98.602% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -45673.228% |
| Summit Therapeutics Inc. | 87.68 Million USD | 93.269% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 84.076% |
| Senti Biosciences, Inc. | 94.7 Million USD | 93.768% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 95.223% |
| Elevation Oncology, Inc. | 45.44 Million USD | 87.013% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | 79.972% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -49.719% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 95.535% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 82.684% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | 30.162% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 96.745% |
| Seer, Inc. | 110.49 Million USD | 94.658% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 91.64% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 93.686% |
| ESSA Pharma Inc. | 32.13 Million USD | 81.633% |
| GlycoMimetics, Inc. | 39.28 Million USD | 84.977% |
| GT Biopharma, Inc. | 13.57 Million USD | 56.526% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 97.315% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 97.065% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 97.725% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 89.602% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 89.087% |
| Alzamend Neuro, Inc. | 9.93 Million USD | 40.61% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 98.538% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 68.82% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 88.357% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 97.727% |
| Aptose Biosciences Inc. | 52.35 Million USD | 88.727% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | 59.043% |
| Soligenix, Inc. | 7.79 Million USD | 24.287% |
| Century Therapeutics, Inc. | 56.07 Million USD | 89.474% |
| Kura Oncology, Inc. | 165.8 Million USD | 96.44% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 94.846% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | 29.054% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -137.827% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 94.52% |
| Autolus Therapeutics plc | 196.72 Million USD | 97.0% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 93.028% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 94.932% |
| Eterna Therapeutics Inc. | 19.38 Million USD | 69.551% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 98.166% |
| GRI Bio, Inc. | 11.33 Million USD | 47.908% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | 16.351% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 95.501% |
| IGM Biosciences, Inc. | 265.59 Million USD | 97.778% |
| INmune Bio, Inc. | 29.89 Million USD | 80.258% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 96.58% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 85.36% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 63.065% |
| Entero Therapeutics, Inc. | 15.74 Million USD | 62.507% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 90.496% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 94.511% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 97.859% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 98.042% |
| Verastem, Inc. | 92.08 Million USD | 93.591% |
| Abeona Therapeutics Inc. | 17.93 Million USD | 67.1% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 96.822% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 95.139% |
| Histogen Inc. | 14.27 Million USD | 58.646% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | 63.223% |
| Surrozen, Inc. | 18.55 Million USD | 68.183% |
| Organovo Holdings, Inc. | 14.91 Million USD | 60.429% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -15.947% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 90.109% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 76.988% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 87.444% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | 22.676% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 96.687% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 87.818% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 97.591% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | 61.592% |
| Apollomics, Inc. | 54.14 Million USD | 89.099% |
| Amarin Corporation plc | 272.35 Million USD | 97.833% |
| Turnstone Biologics Corp. | 78.33 Million USD | 92.466% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 97.582% |
| Synaptogenix, Inc. | 8.31 Million USD | 29.01% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | 59.537% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 97.668% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | 82.292% |
| Monopar Therapeutics Inc. | 8.83 Million USD | 33.169% |
| Exelixis, Inc. | 1.58 Billion USD | 99.628% |
| Better Therapeutics, Inc. | 38.26 Million USD | 84.575% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 97.457% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 99.31% |
| NLS Pharmaceutics AG | 11.8 Million USD | 50.013% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | 26.609% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 80.322% |
| Gritstone bio, Inc. | 148.37 Million USD | 96.022% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 91.429% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | 63.925% |
| Avid Bioservices, Inc. | 25.99 Million USD | 77.297% |
| Insmed Incorporated | 949.26 Million USD | 99.378% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | 62.383% |
| MediWound Ltd. | 18.86 Million USD | 68.72% |
| OmniAb, Inc. | 83.89 Million USD | 92.965% |
| Alector, Inc. | 248.8 Million USD | 97.628% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 97.481% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 88.705% |
| Zai Lab Limited | 547.47 Million USD | 98.922% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 98.52% |
| Aura Biosciences, Inc. | 84.99 Million USD | 93.056% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 97.612% |
| Immunic, Inc. | 99.22 Million USD | 94.052% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 96.288% |
| Veracyte, Inc. | 357.93 Million USD | 98.351% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.935% |
| FibroGen, Inc. | 398.11 Million USD | 98.518% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 58.466% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | 14.314% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | 17.173% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 99.819% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | 77.189% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 98.135% |
| TG Therapeutics, Inc. | 198.47 Million USD | 97.026% |
| Galecto, Inc. | 35.62 Million USD | 83.434% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 85.495% |
| Fortrea Holdings Inc. | 457.3 Million USD | 98.709% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 89.126% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | 79.562% |
| XBiotech Inc. | 37.51 Million USD | 84.266% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 91.429% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | 71.418% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 95.845% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 94.043% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 94.669% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 99.384% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | 79.539% |
| Vaxxinity, Inc. | 56.05 Million USD | 89.47% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 98.629% |
| Gain Therapeutics, Inc. | 22.3 Million USD | 73.543% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 94.677% |
| NexImmune, Inc. | 28.16 Million USD | 79.047% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -6.709% |
| Marker Therapeutics, Inc. | 17.89 Million USD | 67.014% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.79% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | 76.818% |
| Scopus BioPharma Inc. | 11.71 Million USD | 49.62% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 95.355% |
| Ainos, Inc. | 12.95 Million USD | 54.434% |
| Pluri Inc. | 22.48 Million USD | 73.746% |
| Prothena Corporation plc | 282.4 Million USD | 97.91% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 97.049% |
| Celularity Inc. | 215.05 Million USD | 97.256% |
| Rallybio Corporation | 78.93 Million USD | 92.523% |
| Cue Biopharma, Inc. | 19.54 Million USD | 69.798% |
| MeiraGTx Holdings plc | 151.07 Million USD | 96.093% |
| Omeros Corporation | 94.75 Million USD | 93.771% |
| Humacyte, Inc. | 23.49 Million USD | 74.882% |
| Immunocore Holdings plc | 308.04 Million USD | 98.084% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -74.1% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 93.206% |
| Blueprint Medicines Corporation | 722.86 Million USD | 99.184% |
| CalciMedica, Inc. | 21.81 Million USD | 72.948% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 92.095% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 96.324% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 96.554% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 97.999% |
| Pulmatrix, Inc. | 22.03 Million USD | 73.219% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 82.93% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 93.359% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 98.93% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 91.865% |
| Cytokinetics, Incorporated | 173.61 Million USD | 96.6% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 82.852% |
| Nutriband Inc. | 5.73 Million USD | -2.929% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 86.467% |
| Vor Biopharma Inc. | 126.03 Million USD | 95.317% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 99.504% |
| Evogene Ltd. | 27.79 Million USD | 78.762% |
| ProKidney Corp. | 151.52 Million USD | 96.105% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 92.043% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | 23.273% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 99.039% |
| CorMedix Inc. | 48.95 Million USD | 87.945% |
| BioLineRx Ltd. | 50.8 Million USD | 88.382% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 96.084% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 84.498% |
| Atai Life Sciences N.V. | 125.78 Million USD | 95.308% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 92.771% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 92.75% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 97.663% |
| Sagimet Biosciences Inc. | 32.74 Million USD | 81.973% |
| MediciNova, Inc. | 10.9 Million USD | 45.855% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 95.418% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | 18.7% |
| GeoVax Labs, Inc. | 6.02 Million USD | 1.996% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 98.761% |
| Biomea Fusion, Inc. | 126.13 Million USD | 95.321% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 99.55% |
| Mereo BioPharma Group plc | 35.84 Million USD | 83.533% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 96.911% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 97.433% |
| Absci Corporation | 73.66 Million USD | 91.988% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 78.602% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 95.582% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 97.563% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 97.748% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 97.162% |
| Allakos Inc. | 196.05 Million USD | 96.99% |
| Imunon, Inc. | 20.31 Million USD | 70.941% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 94.799% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 98.399% |
| BioAtla, Inc. | 129.68 Million USD | 95.449% |
| NLS Pharmaceutics AG | 11.8 Million USD | 50.013% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 62.747% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 93.05% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 85.866% |
| XOMA Corporation | 46.46 Million USD | 87.297% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 94.691% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 95.857% |
| aTyr Pharma, Inc. | 12.97 Million USD | 54.527% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 94.306% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 96.586% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 97.683% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 84.223% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | 28.242% |
| Akari Therapeutics, Plc | 16.8 Million USD | 64.882% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -159.546% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 98.028% |
| Lexaria Bioscience Corp. | 6.72 Million USD | 12.287% |
| UroGen Pharma Ltd. | 138.88 Million USD | 95.751% |
| Sutro Biopharma, Inc. | 243 Million USD | 97.571% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | 18.869% |
| Orgenesis Inc. | 45.75 Million USD | 87.101% |
| Entera Bio Ltd. | 8.86 Million USD | 33.386% |
| GH Research PLC | 41.22 Million USD | 85.682% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | 77.042% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 92.894% |
| Xencor, Inc. | 306.97 Million USD | 98.077% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -19.629% |
| Replimune Group, Inc. | 234.77 Million USD | 97.486% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | 71.196% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 96.923% |
| Lexaria Bioscience Corp. | 6.72 Million USD | 12.287% |
| Portage Biotech Inc. | 18.19 Million USD | 67.57% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | 18.7% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 94.377% |
| OncoCyte Corporation | 25.63 Million USD | 76.979% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | 3.176% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | 48.486% |
| Purple Biotech Ltd. | -22.46 Million USD | 126.27% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | 64.187% |
| scPharmaceuticals Inc. | 65.17 Million USD | 90.945% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | 30.176% |
| HilleVax, Inc. | 133.34 Million USD | 95.574% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | 42.615% |
| Tharimmune, Inc. | 9.45 Million USD | 37.579% |
| Genprex, Inc. | 31.06 Million USD | 80.998% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 96.853% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | 81.19% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -671.503% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -8.355% |
| OKYO Pharma Limited | 8243.57 USD | -71495.195% |
| Savara Inc. | 15.74 Million USD | 62.515% |
| Curis, Inc. | 58.35 Million USD | 89.886% |
| Daré Bioscience, Inc. | 33.6 Million USD | 82.439% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -15.896% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | 20.895% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | 78.159% |
| BeiGene, Ltd. | 3.28 Billion USD | 99.82% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 70.4% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 98.817% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 96.159% |
| Erasca, Inc. | 141.52 Million USD | 95.83% |
| bluebird bio, Inc. | 240.23 Million USD | 97.543% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -30.374% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 99.662% |
| DBV Technologies S.A. | 92.16 Million USD | 93.596% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -30.374% |
| Moderna, Inc. | 6.39 Billion USD | 99.908% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 86.148% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | 58.917% |
| Molecular Templates, Inc. | 63.09 Million USD | 90.645% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 91.152% |
| Travere Therapeutics, Inc. | 472 Million USD | 98.75% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 95.882% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 90.493% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 86.405% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 97.164% |
| MacroGenics, Inc. | 217.21 Million USD | 97.283% |
| RenovoRx, Inc. | 11.39 Million USD | 48.21% |
| Adicet Bio, Inc. | 152.03 Million USD | 96.118% |
| Prime Medicine, Inc. | 186.63 Million USD | 96.838% |
| Aditxt, Inc. | 25.95 Million USD | 77.257% |
| Adagene Inc. | 41.83 Million USD | 85.891% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | 19.262% |
| Quantum-Si incorporated | 111.65 Million USD | 94.714% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 96.566% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | 59.514% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 83.524% |
| SciSparc Ltd. | 9.01 Million USD | 34.502% |
| Vericel Corporation | 142.04 Million USD | 95.845% |
| Revelation Biosciences, Inc. | 8.65 Million USD | 31.821% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | 74.438% |
| Generation Bio Co. | 144.46 Million USD | 95.915% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 92.892% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 93.174% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 98.004% |
| Invivyd, Inc. | 205.75 Million USD | 97.132% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 91.821% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | 37.069% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 92.157% |
| Artelo Biosciences, Inc. | 10.28 Million USD | 42.627% |
| 2seventy bio, Inc. | 289.88 Million USD | 97.964% |
| ADMA Biologics, Inc. | 66.58 Million USD | 91.136% |
| Clene Inc. | 41.07 Million USD | 85.63% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | 53.919% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 89.229% |
| GeoVax Labs, Inc. | 6.02 Million USD | 1.996% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 98.324% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 83.932% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | 82.501% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 94.309% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 81.89% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 96.534% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 99.231% |
| Evaxion Biotech A/S | 22.27 Million USD | 73.498% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 95.646% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 97.487% |
| Trevena, Inc. | 38.41 Million USD | 84.635% |
| Surrozen, Inc. | 18.55 Million USD | 68.183% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 92.617% |
| Cingulate Inc. | 22.75 Million USD | 74.068% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 178.777% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 86.787% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | 28.321% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 94.245% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 99.217% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 90.492% |
| Clearmind Medicine Inc. | 8.74 Million USD | 32.482% |
| Kronos Bio, Inc. | 128.11 Million USD | 95.393% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 92.98% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -101.228% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 94.146% |
| Statera Biopharma, Inc. | 28.82 Million USD | 79.528% |
| ImmunityBio, Inc. | 362.87 Million USD | 98.374% |
| Korro Bio, Inc. | 84.53 Million USD | 93.018% |
| Kineta, Inc. | 21.15 Million USD | 72.102% |
| BioVie Inc. | 31.95 Million USD | 81.528% |
| Codexis, Inc. | 66.51 Million USD | 91.127% |
| Celularity Inc. | 215.05 Million USD | 97.256% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 97.396% |
| Celcuity Inc. | 66.23 Million USD | 91.089% |
| Virax Biolabs Group Limited | 6.54 Million USD | 9.853% |
| Cibus, Inc. | 320.3 Million USD | 98.157% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 86.274% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 82.561% |
| IN8bio, Inc. | 30.33 Million USD | 80.545% |
| Kodiak Sciences Inc. | 277.32 Million USD | 97.872% |
| Annexon, Inc. | 143.72 Million USD | 95.893% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 95.374% |
| Assembly Biosciences, Inc. | 22.9 Million USD | 74.237% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -822.188% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 99.243% |
| Eyenovia, Inc. | 25.4 Million USD | 76.77% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 95.794% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -6.113% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 92.542% |
| Arcellx, Inc. | 200.19 Million USD | 97.052% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 87.142% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 97.273% |
| Regulus Therapeutics Inc. | 9.95 Million USD | 40.725% |
| Moolec Science SA | 52.75 Million USD | 88.812% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 90.346% |
| Geron Corporation | 70.44 Million USD | 91.621% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 87.318% |
| Royalty Pharma plc | 862.4 Million USD | 99.316% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 93.726% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | 36.727% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | 73.918% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 97.16% |
| Humacyte, Inc. | 23.49 Million USD | 74.882% |
| Structure Therapeutics Inc. | 102.77 Million USD | 94.257% |
| 89bio, Inc. | 151.2 Million USD | 96.097% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 92.635% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | 59.409% |
| Genelux Corporation | 24.33 Million USD | 75.747% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 82.602% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 96.586% |
| Notable Labs, Ltd. | 14.77 Million USD | 60.041% |
| Liquidia Corporation | 87.98 Million USD | 93.292% |
| Mustang Bio, Inc. | 48.5 Million USD | 87.831% |
| Immunovant, Inc. | 282.7 Million USD | 97.912% |
| Quantum-Si incorporated | 111.65 Million USD | 94.714% |
| Arbutus Biopharma Corporation | 22.54 Million USD | 73.82% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | 72.248% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 94.214% |
| Acasti Pharma Inc. | 11.3 Million USD | 47.775% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | 74.251% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | 63.065% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 87.319% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -420.192% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | 62.848% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | 79.758% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 85.738% |
| PepGen Inc. | 84.76 Million USD | 93.037% |
| Moleculin Biotech, Inc. | 29.63 Million USD | 80.082% |
| United Therapeutics Corporation | 885.1 Million USD | 99.333% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | 74.224% |
| Solid Biosciences Inc. | 104.31 Million USD | 94.342% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | 81.965% |
| Immuneering Corporation | 58.41 Million USD | 89.896% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -15.947% |
| Silo Pharma, Inc. | 3.92 Million USD | -50.49% |
| Belite Bio, Inc | 31.66 Million USD | 81.363% |
| XOMA Corporation | 46.46 Million USD | 87.297% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 91.263% |
| Bionomics Limited | 17.89 Billion USD | 99.967% |
| Apogee Therapeutics, Inc. | 93 Million USD | 93.654% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 116.541% |
| uniQure N.V. | 285.08 Million USD | 97.93% |
| Cassava Sciences, Inc. | 105.95 Million USD | 94.43% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | 19.262% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 96.961% |
| Forte Biosciences, Inc. | 32.47 Million USD | 81.827% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | 28.966% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | 79.922% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -6.113% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | 58.466% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | 33.603% |
| Altimmune, Inc. | 30.55 Million USD | 80.685% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 98.62% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 116.541% |
| Compugen Ltd. | 43.97 Million USD | 86.578% |
| Peak Bio, Inc. | 1249.13 USD | -472388.852% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 92.037% |
| Benitec Biopharma Inc. | 22.38 Million USD | 73.631% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 97.573% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | 79.322% |
| Zura Bio Limited | 62.63 Million USD | 90.578% |
| PolyPid Ltd. | 21.04 Million USD | 71.955% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | 63.738% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | 79.322% |
| Instil Bio, Inc. | 85.78 Million USD | 93.12% |
| argenx SE | 1.53 Billion USD | 99.615% |
| Immunome, Inc. | 122.82 Million USD | 95.195% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 87.824% |
| Verona Pharma plc | 67.15 Million USD | 91.211% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | 77.199% |
| Shattuck Labs, Inc. | 93.61 Million USD | 93.695% |
| CervoMed Inc. | 14.95 Million USD | 60.542% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 91.652% |
| Plus Therapeutics, Inc. | 8.54 Million USD | 30.922% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 88.427% |
| Moolec Science SA | 52.75 Million USD | 88.812% |
| Enveric Biosciences, Inc. | 16.44 Million USD | 64.118% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 95.548% |
| AnaptysBio, Inc. | 181.56 Million USD | 96.749% |
| Design Therapeutics, Inc. | 78.19 Million USD | 92.452% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 93.219% |
| NeurAxis, Inc. | 8.82 Million USD | 33.093% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | 53.103% |
| Lumos Pharma, Inc. | 38.66 Million USD | 84.736% |
| Achilles Therapeutics plc | 75.25 Million USD | 92.157% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | 77.199% |
| 180 Life Sciences Corp. | 13.47 Million USD | 56.208% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | 77.73% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -101.228% |
| Nutriband Inc. | 5.73 Million USD | -2.929% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 94.672% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 89.395% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 88.4% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 91.071% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 89.095% |
| Palisade Bio, Inc. | 13.32 Million USD | 55.691% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 87.003% |
| Beam Therapeutics Inc. | 554.19 Million USD | 98.935% |
| Neurogene Inc. | 55.58 Million USD | 89.382% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 97.625% |
| AEON Biopharma, Inc. | 48.42 Million USD | 87.813% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 93.897% |
| Sesen Bio, Inc. | 78.38 Million USD | 92.47% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 92.934% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | 53.11% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 98.691% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 93.285% |
| Athira Pharma, Inc. | 125.46 Million USD | 95.296% |
| Vaccinex, Inc. | 23.45 Million USD | 74.837% |
| HCW Biologics Inc. | 21.02 Million USD | 71.932% |
| XOMA Corporation | 46.46 Million USD | 87.297% |
| Nektar Therapeutics | 190.9 Million USD | 96.908% |
| Arvinas, Inc. | 480 Million USD | 98.77% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -159.546% |
| Merus N.V. | 200.49 Million USD | 97.056% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 94.29% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 82.952% |
| Rezolute, Inc. | 70.38 Million USD | 91.615% |
| Clene Inc. | 41.07 Million USD | 85.63% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | 63.965% |
| BeyondSpring Inc. | 24.86 Million USD | 76.264% |
| Synlogic, Inc. | 58.53 Million USD | 89.917% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | 67.013% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -31.389% |
| Peak Bio, Inc. | 1249.13 USD | -472388.852% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 90.236% |
| Krystal Biotech, Inc. | 160.42 Million USD | 96.321% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 97.819% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 98.304% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -173.655% |
| MannKind Corporation | 125.59 Million USD | 95.301% |
| Ikena Oncology, Inc. | 84.57 Million USD | 93.022% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | 38.82% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 93.413% |
| Gossamer Bio, Inc. | 183.75 Million USD | 96.788% |
| CohBar, Inc. | 12.38 Million USD | 52.358% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 88.364% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 78.602% |
| Legend Biotech Corporation | 583.14 Million USD | 98.988% |
| Mural Oncology plc | 192.07 Million USD | 96.927% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 91.21% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 63.444% |
| Disc Medicine, Inc. | 91.12 Million USD | 93.523% |
| Champions Oncology, Inc. | 28.11 Million USD | 79.004% |
| REGENXBIO Inc. | 321.15 Million USD | 98.162% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -10.087% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 89.415% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 84.851% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 94.839% |
| Vaxart, Inc. | 90.72 Million USD | 93.495% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | 30.728% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 86.208% |
| Cellectis S.A. | 97.32 Million USD | 93.935% |
| Longeveron Inc. | 21.25 Million USD | 72.226% |
| Repare Therapeutics Inc. | 167.35 Million USD | 96.473% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 99.566% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 92.198% |
| Revolution Medicines, Inc. | 498.76 Million USD | 98.817% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | 11.275% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 86.572% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 92.087% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 91.524% |
| Anixa Biosciences, Inc. | 11.06 Million USD | 46.637% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.876% |
| Denali Therapeutics Inc. | 527.23 Million USD | 98.881% |
| Revelation Biosciences, Inc. | 8.65 Million USD | 31.821% |
| Veru Inc. | 101.34 Million USD | 94.177% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | 74.785% |
| Cingulate Inc. | 22.75 Million USD | 74.068% |
| Passage Bio, Inc. | 108.38 Million USD | 94.555% |
| Context Therapeutics Inc. | 25.07 Million USD | 76.46% |
| Exicure, Inc. | 14.07 Million USD | 58.07% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 97.136% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 86.37% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | 35.689% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 97.662% |
| Nuvalent, Inc. | 149.49 Million USD | 96.052% |
| ABVC BioPharma, Inc. | 8.06 Million USD | 26.837% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 94.306% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | 72.484% |
| OmniAb, Inc. | 83.89 Million USD | 92.965% |
| Anew Medical, Inc. | 1.3 Million USD | -353.706% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | 81.986% |
| Lipocine Inc. | 15.08 Million USD | 60.862% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 91.386% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 92.25% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 85.36% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 94.861% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | 73.633% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 99.111% |
| Ocugen, Inc. | 71.56 Million USD | 91.753% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 93.712% |
| Q32 Bio Inc. | 92.68 Million USD | 93.632% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | 72.126% |
| Alumis Inc. Common Stock | 158.17 Million USD | 96.269% |
| Equillium, Inc. | 50.6 Million USD | 88.337% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 90.543% |
| Coya Therapeutics, Inc. | 13.9 Million USD | 57.557% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | 68.715% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 87.429% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 94.559% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 52.375% |
| Dominari Holdings Inc. | 23.83 Million USD | 75.238% |
| Edesa Biotech, Inc. | 9.22 Million USD | 36.006% |
| vTv Therapeutics Inc. | 11.9 Million USD | 50.433% |
| Bio-Techne Corporation | 563.03 Million USD | 98.952% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 98.556% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 97.804% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 95.538% |
| Candel Therapeutics, Inc. | 14.41 Million USD | 59.045% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 96.395% |
| Nkarta, Inc. | 131.65 Million USD | 95.517% |
| BioCardia, Inc. | 12.12 Million USD | 51.308% |
| Iterum Therapeutics plc | 47.46 Million USD | 87.566% |